Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
Yoshimasa Shiraishi(Kyushu University), Isamu Okamoto(Kyushu University Hospital), Masafumi Yamaguchi(National Hospital Organization Kyushu Cancer Center), Shuji Murakami(Kanagawa Cancer Center), Kazuo Kasahara(Nippon Medical School), Satoshi Hara(Itami City Hospital), Takashi Kijima(Hyogo University), Toshihide Yokoyama(Kurashiki Central Hospital), Haruhiko Fukuda(National Cancer Center Hospital East), Shinnosuke Takemoto(Nagasaki University), Hidetoshi Hayashi(Kindai University), Seiji Niho(Dokkyo Medical University), Koichi Azuma(Kyushu University Hospital), Yuichiro Ohe(National Cancer Center), Kiyotaka Yoh(National Cancer Center Hospital East), Yutaka Fujiwara(Aichi Cancer Center), Takayasu Kurata(Kansai Medical University), Ryo Morita, Shogo Nomura(Juntendo University), Hidehito Horinouchi(Tokyo National Hospital), Toshiyuki Kozuki(Shikoku Cancer Center), Masahiko Ando(Nagoya University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Hiroyasu Kaneda(Osaka City University), Hiroaki Akamatsu(Army Medical University), Masaki Okamoto(Kurume University), Yuta Sekino(Japan Clinical Cancer Research Organization), Yasuto Yoneshima(Kyushu University), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Shintaro Kanda(Shinshu University Hospital)
Cited by 43
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k